Dermira Inc. (NASDAQ:DERM) CEO Thomas G. Wiggans sold 11,000 shares of the business’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $34.60, for a total value of $380,600.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Shares of Dermira Inc. (NASDAQ:DERM) opened at 34.76 on Monday. The firm’s 50-day moving average price is $33.30 and its 200 day moving average price is $29.61. The company’s market cap is $1.23 billion. Dermira Inc. has a 52 week low of $17.42 and a 52 week high of $36.16.
Dermira (NASDAQ:DERM) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.03. On average, equities research analysts forecast that Dermira Inc. will post ($3.46) EPS for the current year.
Institutional investors have recently made changes to their positions in the company. Strs Ohio boosted its position in shares of Dermira by 72.6% in the second quarter. Strs Ohio now owns 12,600 shares of the biopharmaceutical company’s stock worth $368,000 after buying an additional 5,300 shares in the last quarter. Eagle Asset Management Inc. boosted its position in shares of Dermira by 4.3% in the second quarter. Eagle Asset Management Inc. now owns 1,344,721 shares of the biopharmaceutical company’s stock worth $39,333,000 after buying an additional 55,991 shares in the last quarter. Hamilton Lane Advisors LLC boosted its position in shares of Dermira by 179.5% in the second quarter. Hamilton Lane Advisors LLC now owns 34,615 shares of the biopharmaceutical company’s stock worth $1,099,000 after buying an additional 22,229 shares in the last quarter. Sphera Funds Management LTD. bought a new position in shares of Dermira during the first quarter worth approximately $2,482,000. Finally, Geode Capital Management LLC boosted its position in shares of Dermira by 7.8% in the first quarter. Geode Capital Management LLC now owns 123,424 shares of the biopharmaceutical company’s stock worth $2,552,000 after buying an additional 8,952 shares in the last quarter. 82.46% of the stock is currently owned by institutional investors.
Several equities analysts recently commented on DERM shares. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, June 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price target on shares of Dermira in a research note on Wednesday, June 22nd. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Dermira in a research note on Wednesday, October 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Dermira currently has a consensus rating of “Buy” and a consensus target price of $41.00.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.